» Articles » PMID: 35881306

Combination of Enzymes and Rutin to Manage Osteoarthritis Symptoms: Lessons from a Narrative Review of the Literature

Overview
Journal Rheumatol Ther
Date 2022 Jul 26
PMID 35881306
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoarthritis is the most common joint disorder affecting over 300 million people worldwide. It typically affects the knees and the hips, and is characterized by a loss in normal joint movement, stiffness, swelling, and pain in patients. The current gold standard therapy for osteoarthritis targets pain management using nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs are associated with several potentially serious side effects, the most common being gastrointestinal perforation and bleeding. Owing to the side effects, NSAID treatment doses need to be as low as possible and should be continued for the shortest duration possible, which is problematic in a chronic condition like osteoarthritis, which requires long-term management. Numerous clinical trials have examined oral enzyme combinations as a potential new approach in managing pain in patients with osteoarthritis. Oral enzyme combinations containing bromelain in combination with trypsin, both proteolytic enzymes, as well as the plant flavonoid rutin, may be an effective alternative to typical NSAIDs. The aim of this narrative review is to summarize and discuss the evidence on the efficacy of oral enzyme combinations compared to the gold standard (NSAID) in the management of osteoarthritis symptoms. Nine randomized controlled trials identified in this review assessed the efficacy and safety of the oral enzyme combination containing bromelain, trypsin, and rutin in patients with osteoarthritis. Most of the studies assessed the impact of the oral enzyme combination on the improvement of the Lequesne Algofunctional index score, treatment-related pain intensity alterations and adverse events compared to patients receiving NSAIDs. Although largely small scale, the study outcomes suggest that this combination is as effective as NSAIDs in the management of osteoarthritis, without the adverse events associated with NSAID use. INFOGRAPHIC.

Citing Articles

Subconjunctival trypsin injection for anterior chamber fibrin exudates in eyes with globe rupture following vitrectomy.

Lu S, Li H, Li X, Ma C, Li X, Hu Q Int J Ophthalmol. 2024; 17(11):2037-2044.

PMID: 39559308 PMC: 11528278. DOI: 10.18240/ijo.2024.11.09.


Anti-inflammatory Role of Trypsin, Rutoside, and Bromelain Combination in Temporomandibular Joint Osteoarthritis: A Systematic Review.

Shekhar A, Maddheshiya N, Adit , Rastogi V, Ramalingam K Cureus. 2024; 16(1):e51749.

PMID: 38322061 PMC: 10846757. DOI: 10.7759/cureus.51749.


The protective activity of natural flavonoids against osteoarthritis by targeting NF-κB signaling pathway.

Ye Y, Zhou J Front Endocrinol (Lausanne). 2023; 14:1117489.

PMID: 36998478 PMC: 10043491. DOI: 10.3389/fendo.2023.1117489.


Tryptase and Exogenous Trypsin: Mechanisms and Ophthalmic Applications.

Ma C, Li H, Lu S, Li X, Wang S, Wang W J Inflamm Res. 2023; 16:927-939.

PMID: 36891173 PMC: 9987324. DOI: 10.2147/JIR.S402900.


Effect of oral enzyme combination, diet and exercise on chronic low-grade inflammatory conditions-a report of three cases.

Pelosi E AME Case Rep. 2023; 7:7.

PMID: 36817707 PMC: 9929666. DOI: 10.21037/acr-22-45.

References
1.
Kirkland J, Tchkonia T . Clinical strategies and animal models for developing senolytic agents. Exp Gerontol. 2014; 68:19-25. PMC: 4412760. DOI: 10.1016/j.exger.2014.10.012. View

2.
Solomon D, Rassen J, Glynn R, Lee J, Levin R, Schneeweiss S . The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010; 170(22):1968-76. DOI: 10.1001/archinternmed.2010.391. View

3.
Hale L, Haynes B . Bromelain treatment of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, CD8, and Leu 8/LAM1 surface molecules and markedly enhances CD2-mediated T cell activation. J Immunol. 1992; 149(12):3809-16. View

4.
Xiang G, Schinzel R, Simm A, Munch G, Sebekova K, Kasper M . Advanced glycation end products (AGEs)-induced expression of TGF-beta 1 is suppressed by a protease in the tubule cell line LLC-PK1. Nephrol Dial Transplant. 2001; 16(8):1562-9. DOI: 10.1093/ndt/16.8.1562. View

5.
Wang S, Wei X, Zhou J, Zhang J, Li K, Chen Q . Identification of α2-macroglobulin as a master inhibitor of cartilage-degrading factors that attenuates the progression of posttraumatic osteoarthritis. Arthritis Rheumatol. 2014; 66(7):1843-53. PMC: 4187342. DOI: 10.1002/art.38576. View